Accolade, Inc. Stock Research

Market Summary

USD11.96-0.72

Market Closed

-5.68%

ACCD Stock Price

ACCD RSI Chart

ACCD Valuation

Market Cap

888.2M

Price/Earnings (Trailing)

-1.92

Price/Sales (Trailing)

2.48

EV/EBITDA

-1.35

Price/Free Cashflow

-20.87

ACCD Price/Sales (Trailing)

ACCD Profitability

EBT Margin

-129.51%

Return on Equity

-95.44%

Return on Assets

-50.75%

Free Cashflow Yield

-4.79%

ACCD Fundamentals

ACCD Revenue

Revenue (TTM)

357.9M

Revenue Y/Y

8.98%

Revenue Q/Q

3.77%

ACCD Earnings

Earnings (TTM)

-463.8M

Earnings Y/Y

-277.19%

Earnings Q/Q

14.3%

Price Action

52 Week Range

4.6119.39

(Low)(High)

Last 7 days

-6.3%

Last 30 days

7.8%

Last 90 days

43.4%

Trailing 12 Months

-14.9%

ACCD Financial Health

Current Ratio

3.14

ACCD Investor Care

Shares Dilution (1Y)

10.66%

Diluted EPS (TTM)

-6.66

Peers (Alternatives to Accolade)

View All Peers In Detail

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
AAPL	2.5T	387.5B	-0.56%	-0.91%	25.94	6.37	2.44%	-5.35%
MSFT	2.1T	204.1B	-1.92%	-6.89%	30.5	10.08	10.38%	-5.25%
GOOG	1.3T	282.8B	1.63%	-25.54%	21.65	4.59	9.78%	-21.12%
AMZN	1.0T	514.0B	-3.36%	-34.72%	-376.42	1.99	9.40%	-108.16%
MID-CAP
NYMT	3.6B	258.4M	203.99%	176.76%	-11.9	13.75	24.91%	-254.56%
JBLU	2.3B	9.2B	-18.97%	-49.38%	-6.41	0.25	51.67%	-98.90%
SMALL-CAP
PLAY	1.7B	1.7B	-22.36%	-14.62%	13.72	0.97	61.79%	371.82%
TLRY	1.6B	602.5M	-17.77%	-52.80%	-2.74	2.63	18.18%	-18.59%
BYND	1.1B	418.9M	5.51%	-56.16%	-2.93	2.57	-9.85%	-101.06%
CGC	991.7M	478.9M	-11.35%	-65.42%	-0.32	2.07	-31.50%	-634.70%
MFA	954.9M	482.4M	-16.25%	-37.64%	-4.12	1.98	33.15%	-170.42%
NKLA	897.6M	50.8M	-34.66%	-77.56%	-1.14	17.66	1229.98%	-13.59%
GPRO	788.4M	1.1B	-10.56%	-33.33%	27.33	0.72	-5.82%	-92.23%
INO	281.8M	10.3M	-24.84%	-63.38%	-1.01	27.46	478.23%	7.85%

Financials for Accolade

Income Statement (Last 12 Months)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Revenue	2.1%	357,873,000	350,377,000	336,022,000	310,021,000	275,497,000
Operating Expenses	12.4%	628,562,000	559,394,000	579,071,000	266,727,000	223,122,000
S&GA Expenses	0.4%	99,204,000	98,797,000	97,870,000	86,765,000	73,004,000
EBITDA	-18.7%	-415,505,000	-350,175,000	-379,660,000	-85,225,000	-
EBITDA Margin	-16.2%	-1.16	-1.00	-1.13	-0.27	-
Earnings Before Taxes	-16.5%	-463,484,000	-397,861,000	-426,796,000	-128,763,000	-102,876,000
EBT Margin	-14.1%	-1.30	-1.14	-1.27	-0.42	-
Interest Expenses	-3.6%	1,589,000	1,648,000	1,648,000	930,000	930,000
Net Income	-15.5%	-463,773,000	-401,398,000	-417,239,000	-123,124,000	-93,294,000
Net Income Margin	-13.1%	-1.30	-1.15	-1.24	-0.40	-
Free Cahsflow	28.5%	-42,555,000	-59,513,000	-67,523,000	-64,871,000	-

* denotes actual numbers (not divided by Millions)
Balance Sheet					(In Millions)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Assets	-1.9%	914	932	944	1,286	1,263
Current Assets	-2.3%	366	375	378	409	408
Cash Equivalents	-1.5%	326	331	336	366	366
Net PPE	10.2%	14.00	12.00	12.00	12.00	12.00
Goodwill	0%	278	278	278	578	580
Liabilities	0.6%	428	425	410	430	475
Current Liabilities	3.5%	117	113	95.00	112	185
Shareholder's Equity	-4.0%	486	506	535	856	789
Retained Earnings	-4.5%	-923	-883	-837	-494	-460
Additional Paid-In Capital	1.4%	1,410	1,390	1,372	1,350	1,249
Shares Outstanding	1.2%	72.00	72.00	70.00	67.00	65.00

Cashflow (Last 12 Months)					(In Thousands)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Cashflow From Operations	29.3%	-40,430	-57,160	-65,197	-62,350	-49,670
Share Based Compensation	-0.6%	81,921	82,392	84,653	72,939	49,093
Cashflow From Investing	-96.9%	-5,347	-2,715	63,827	-263,613	-263,572
Cashflow From Financing	-16.5%	5,432	6,505	11,490	257,932	260,286

Risks for ACCD

What is the probability of a big loss on ACCD?

81.7%

Probability that Accolade stock will be more than 20% underwater in next one year

75.3%

Probability that Accolade stock will be more than 30% underwater in next one year.

49.3%

Probability that Accolade stock will be more than 40% underwater in next one year.

*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does ACCD drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Accolade was unfortunately bought at previous high price.

Drawdowns

Returns for ACCD

Cumulative Returns on ACCD

Which funds bought or sold ACCD recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
2023-03-06	Rockefeller Capital Management L.P.	added	37.04	-6,000	86,000	-%
2023-02-28	Voya Investment Management LLC	unchanged	-	-89,824	193,176	-%
2023-02-27	Parallax Volatility Advisers, L.P.	new	-	48,937	48,937	-%
2023-02-21	NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO	new	-	1,948	1,948	-%
2023-02-21	MACQUARIE GROUP LTD	sold off	-100	-18,000	-	-%
2023-02-17	EQUITABLE TRUST CO	unchanged	-	-562,394	1,207,610	0.10%
2023-02-15	JANE STREET GROUP, LLC	added	197	1,414,870	2,786,870	-%
2023-02-15	MetLife Investment Management, LLC	unchanged	-	-125,310	269,690	-%
2023-02-15	ALLIANCEBERNSTEIN L.P.	unchanged	-	-273,033	584,967	-%
2023-02-15	Metropolitan Life Insurance Co/NY	unchanged	-	-14,416	30,584	-%

Latest Funds Activity

Are funds buying ACCD calls or puts?

Calls

Puts

Are funds bullish or bearish(Calls - Puts)?

Net Call Options

No. of funds that own ACCD

No. of Funds

Accolade News

Schedule 13G FIlings of Accolade

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2023	bellevue group ag	5.1%	3,677,277	SC 13G
Feb 09, 2023	vanguard group inc	6.83%	4,916,397	SC 13G/A
Feb 09, 2023	brown advisory inc	6.9%	4,988,021	SC 13G
Jan 31, 2023	blackrock inc.	7.3%	5,265,682	SC 13G/A
Jan 06, 2023	jpmorgan chase & co	7.2%	5,196,148	SC 13G
Feb 14, 2022	andreessen horowitz fund iv, l.p.	2.4%	1,619,088	SC 13G/A
Feb 09, 2022	ark investment management llc	7.54%	5,029,148	SC 13G
Feb 09, 2022	vanguard group inc	7.56%	5,040,150	SC 13G
Feb 04, 2022	blackrock inc.	5.2%	3,489,312	SC 13G
Feb 16, 2021	andreessen horowitz fund iv, l.p.	2.5%	1,394,563	SC 13G

ACCD Fair Value

Recent SEC filings of Accolade

View All Filings

Date Filed	Form Type	Document
Mar 20, 2023	4	Insider Trading
Mar 20, 2023	4	Insider Trading
Mar 20, 2023	4	Insider Trading
Mar 20, 2023	4	Insider Trading
Mar 17, 2023	144	Notice of Insider Sale Intent
Mar 17, 2023	144	Notice of Insider Sale Intent
Mar 02, 2023	4	Insider Trading
Mar 02, 2023	4	Insider Trading
Mar 02, 2023	4	Insider Trading
Feb 28, 2023	8-K	Current Report

Latest Insider Trading transactions for ACCD

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
2023-02-28	BRODSKY JEFFREY S	acquired	-	-	1,207	-
2023-02-28	Klein Peter S	acquired	-	-	604	-
2023-02-17	Barnes Stephen H.	sold	-1,684	11.9464	-141	chief financial officer
2023-02-17	HILTON MICHAEL W	sold	-1,206	11.9464	-101	-
2023-02-17	Cavanaugh Robert N	sold	-2,150	11.9464	-180	president
2023-02-17	SINGH RAJEEV	sold	-3,368	11.9464	-282	chief executive officer
2023-02-16	Cavanaugh Robert N	acquired	-	-	510	president
2023-02-16	SINGH RAJEEV	acquired	-	-	933	chief executive officer
2023-02-16	Barnes Stephen H.	acquired	-	-	414	chief financial officer
2023-02-16	HILTON MICHAEL W	acquired	-	-	332	-

About Accolade

Rajeev Singh

www.accolade.com

2350

Accolade, Inc. develops and provides technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based technology and multimodal support from a team of health assistants and clinicians, including nurses, physician medical directors, and behavioral health specialists. It also provides second opinion consultation and health care decision support services. The company serves employers who provide their employees and their employees' families a single place to turn for their health, healthcare, and benefits needs. Accolade, Inc. was founded in 2007 and is headquartered in Plymouth Meeting, Pennsylvania.

ACCD Income Statement

2022-11-30

Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Nov. 30, 2022	Nov. 30, 2021	Nov. 30, 2022	Nov. 30, 2021
Condensed Consolidated Statements of Operations
Revenue	$ 90,946	$ 83,450	$ 264,117	$ 216,265
Cost of revenue, excluding depreciation and amortization	50,412	45,156	147,857	125,426
Operating expenses:
Product and technology	24,254	22,846	77,265	61,297
Sales and marketing	25,023	24,616	75,573	63,134
General and administrative	20,037	21,464	61,295	69,636
Depreciation and amortization	11,602	11,250	34,749	30,967
Goodwill impairment			299,705
Change in fair value of contingent consideration		(68,428)		(38,282)
Total operating expenses	80,916	11,748	548,587	186,752
Income (loss) from operations	(40,382)	26,546	(432,327)	(95,913)
Interest income (expense), net	386	(743)	(484)	(2,137)
Other income (expense)	201	25	21	(19)
Income (loss) before income taxes	(39,795)	25,828	(432,790)	(98,069)
Income tax benefit (expense)	(77)	(3,325)	3,573	9,501
Net income (loss)	$ (39,872)	$ 22,503	$ (429,217)	$ (88,568)
Net income (loss) per share, Basic	$ (0.56)	$ 0.34	$ (6.07)	$ (1.41)
Net income (loss) per share, Diluted	$ (0.56)	$ 0.31	$ (6.07)	$ (1.41)
Weighted-average common shares outstanding, Basic	71,228,351	65,418,728	70,755,157	62,684,823
Weighted-average common shares outstanding, Diluted	71,228,351	71,490,045	70,755,157	62,684,823

ACCD Balance Sheet

2022-11-30

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Nov. 30, 2022	Feb. 28, 2022
Current assets:
Cash and cash equivalents	$ 325,637	$ 365,853
Accounts receivable, net	20,483	21,116
Unbilled revenue	3,702	9,685
Current portion of deferred contract acquisition costs	4,075	3,015
Prepaid and other current assets	12,334	9,468
Total current assets	366,231	409,137
Property and equipment, net	13,561	11,797
Operating lease right-of-use assets	30,936	33,126
Goodwill	278,191	577,896
Intangible assets, net	213,574	244,690
Deferred contract acquisition costs	9,981	7,205
Other assets	1,317	1,678
Total assets	913,791	1,285,529
Current liabilities:
Accounts payable	9,987	7,837
Accrued expenses and other current liabilities	11,026	11,000
Accrued compensation	35,467	39,189
Due to customers	9,244	16,263
Current portion of deferred revenue	43,500	30,875
Current portion of operating lease liabilities	7,392	6,589
Total current liabilities	116,616	111,753
Loans payable, net of unamortized issuance costs	281,914	280,666
Operating lease liabilities	28,849	32,486
Other noncurrent liabilities	203	4,562
Deferred revenue	256	268
Total liabilities	427,838	429,735
Commitments and Contingencies (note 12)
Stockholders' equity
Common stock par value $0.0001; 500,000,000 shares authorized; 72,390,727 and 67,098,477 shares issued and outstanding at November 30, 2022 and February 28, 2022, respectively	7	7
Additional paid-in capital	1,409,807	1,350,431
Accumulated deficit	(923,861)	(494,644)
Total stockholders' equity	485,953	855,794
Total liabilities and stockholders' equity	$ 913,791	$ 1,285,529